Product Description
A long-acting, pegylated, recombinant analog of the endogenous human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Upon administration, mecapegfilgrastim binds to and activates specific cell surface receptors and stimulates neutrophil progenitor proliferation and differentiation, as well as selected neutrophil functions. This may decrease the duration and incidence of chemotherapy-induced neutropenia (CIN). Pegylation significantly increases the therapeutic half-life. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/mecapegfilgrastim?redirect=true)
Mechanisms of Action: G-CSF Cleaver
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hengrui Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Breast Cancer|Neutropenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SYSKY-2022-105-01 | P2 |
Recruiting |
Neutropenia|Breast Cancer |
2023-12-01 |